Nifty
Sensex
:
:
11050.25
37388.66
244.70 (2.26%)
835.06 (2.28%)

Pharmaceuticals & Drugs - Global

Rating :
71/99  (View)

BSE: 532523 | NSE: BIOCON

428.00
19.75 (4.84%)
25-Sep-2020 | 3:58PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  414.65
  •  430.55
  •  410.50
  •  408.25
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  4535634
  •  19412.51
  •  463.90
  •  212.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 51,348.00
  • 74.28
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 52,974.80
  • N/A
  • 7.59

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.67%
  • 1.03%
  • 10.55%
  • FII
  • DII
  • Others
  • 15.93%
  • 5.41%
  • 6.41%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.43
  • 13.72
  • 15.58

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -5.97
  • 10.36
  • 8.68

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.78
  • 8.01
  • 30.32

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 23.29
  • 38.93
  • 53.62

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.20
  • 5.18
  • 6.16

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.58
  • 23.26
  • 27.69

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Net Sales
1,671
1,466
14%
1,581
1,529
3%
1,748
1,541
13%
1,572
1,321
19%
Expenses
1,258
1,028
22%
1,262
1,126
12%
1,304
1,160
12%
1,169
981
19%
EBITDA
413
438
-6%
319
403
-21%
444
381
17%
403
340
19%
EBIDTM
25%
30%
14%
26%
25%
25%
26%
26%
Other Income
18
24
-24%
63
28
124%
36
26
40%
38
54
-29%
Interest
12
17
-25%
17
16
6%
18
19
-5%
14
19
-27%
Depreciation
167
124
34%
152
120
27%
144
117
23%
132
112
17%
PBT
252
321
-21%
212
296
-28%
318
277
15%
363
452
-20%
Tax
81
85
-5%
45
41
10%
85
46
84%
100
73
37%
PAT
171
236
-27%
168
255
-34%
234
231
1%
263
379
-30%
PATM
10%
16%
7%
17%
13%
15%
17%
29%
EPS
1.43
1.96
-27%
1.40
2.12
-34%
1.95
1.92
2%
2.19
3.16
-31%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
6,573
6,367
5,514
4,123
3,891
3,347
3,090
2,877
2,485
2,086
1,806
Net Sales Growth
12%
15%
34%
6%
16%
8%
7%
16%
19%
16%
 
Cost Of Goods Sold
6,241
2,052
1,897
1,636
1,447
1,290
1,256
1,186
1,044
852
725
Gross Profit
332
4,315
3,618
2,487
2,444
2,057
1,834
1,691
1,441
1,234
1,081
GP Margin
5%
68%
66%
60%
63%
61%
59%
59%
58%
59%
60%
Total Expenditure
4,994
5,110
4,121
3,294
2,912
2,580
2,394
2,190
1,946
1,809
2,213
Power & Fuel Cost
-
246
240
189
156
185
177
162
143
97
82
% Of Sales
-
4%
4%
5%
4%
6%
6%
6%
6%
5%
5%
Employee Cost
-
1,459
1,165
931
747
610
533
466
389
308
239
% Of Sales
-
23%
21%
23%
19%
18%
17%
16%
16%
15%
13%
Manufacturing Exp.
-
865
451
336
392
204
81
63
95
113
82
% Of Sales
-
14%
8%
8%
10%
6%
3%
2%
4%
5%
5%
General & Admin Exp.
-
182
53
57
22
145
166
132
122
93
82
% Of Sales
-
3%
1%
1%
1%
4%
5%
5%
5%
4%
5%
Selling & Distn. Exp.
-
270
278
98
107
101
109
119
100
89
62
% Of Sales
-
4%
5%
2%
3%
3%
4%
4%
4%
4%
3%
Miscellaneous Exp.
-
36
37
47
41
45
73
62
53
257
62
% Of Sales
-
1%
1%
1%
1%
1%
2%
2%
2%
12%
52%
EBITDA
1,579
1,257
1,394
829
980
768
696
687
539
277
-407
EBITDA Margin
24%
20%
25%
20%
25%
23%
23%
24%
22%
13%
-23%
Other Income
156
508
144
206
157
79
53
56
57
309
1,036
Interest
61
65
71
62
26
29
9
2
8
12
24
Depreciation
595
552
448
385
277
249
221
204
179
176
157
PBT
1,146
1,147
1,019
589
833
569
519
538
408
398
447
Tax
311
315
212
157
162
142
96
107
98
56
72
Tax Rate
27%
26%
17%
27%
19%
19%
15%
20%
16%
14%
16%
PAT
836
777
904
351
596
529
497
414
509
342
368
PAT before Minority Interest
752
900
1,002
432
672
587
528
431
513
342
375
Minority Interest
-84
-123
-97
-81
-76
-59
-31
-17
-4
-1
-8
PAT Margin
13%
12%
16%
9%
15%
16%
16%
14%
20%
16%
20%
PAT Growth
-24%
-14%
158%
-41%
13%
6%
20%
-19%
49%
-7%
 
EPS
6.96
6.48
7.54
2.93
4.97
4.41
4.15
3.45
4.24
2.85
3.06

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
6,706
6,098
5,181
4,838
4,034
3,271
3,027
2,695
2,272
2,033
Share Capital
600
300
300
100
100
100
100
100
100
100
Total Reserves
5,997
5,721
4,812
4,670
3,934
3,133
2,806
2,492
2,080
1,850
Non-Current Liabilities
2,685
2,123
2,006
2,305
2,421
1,378
1,262
666
645
456
Secured Loans
1,221
1,540
1,787
2,104
2,061
758
580
124
9
0
Unsecured Loans
1
2
3
4
11
11
26
40
60
66
Long Term Provisions
86
66
49
36
30
15
8
4
0
1
Current Liabilities
4,008
3,038
2,141
1,678
1,666
1,555
1,380
990
1,016
1,061
Trade Payables
1,325
1,198
1,005
740
610
429
347
346
348
296
Other Current Liabilities
1,784
1,374
870
698
527
706
612
313
269
376
Short Term Borrowings
668
261
130
97
395
261
244
85
187
247
Short Term Provisions
231
204
136
143
134
158
177
246
212
141
Total Liabilities
14,076
11,868
9,796
9,197
8,387
6,375
5,751
4,416
3,937
3,587
Net Block
5,971
4,471
3,700
3,625
1,748
1,630
1,525
1,510
1,270
1,316
Gross Block
9,147
7,095
5,874
5,436
3,404
3,034
2,702
2,481
2,066
1,966
Accumulated Depreciation
3,176
2,624
2,174
1,811
1,655
1,404
1,176
971
796
650
Non Current Assets
8,751
7,045
5,648
5,149
4,416
3,813
3,112
2,176
1,938
1,779
Capital Work in Progress
2,196
1,899
1,303
839
2,240
1,676
1,206
312
390
262
Non Current Investment
108
182
64
189
27
0
64
64
64
61
Long Term Loans & Adv.
402
402
437
320
350
337
252
242
181
140
Other Non Current Assets
73
91
144
176
51
170
64
47
32
0
Current Assets
5,325
4,823
4,149
4,048
3,971
2,563
2,639
2,240
2,000
1,807
Current Investments
858
829
611
1,065
875
230
700
522
492
400
Inventories
1,436
1,032
722
635
542
453
377
398
378
414
Sundry Debtors
1,224
1,292
1,064
883
714
770
600
510
492
496
Cash & Bank
999
1,057
1,323
1,044
1,539
938
804
673
523
442
Other Current Assets
809
566
373
396
301
172
158
137
114
57
Short Term Loans & Adv.
266
46
55
24
227
76
82
81
37
20
Net Current Assets
1,317
1,785
2,007
2,369
2,305
1,008
1,259
1,250
984
747
Total Assets
14,076
11,868
9,796
9,197
8,387
6,375
5,751
4,416
3,937
3,587

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
1,283
1,155
662
640
371
211
561
471
564
798
PBT
871
1,215
610
850
751
624
538
610
395
447
Adjustment
921
260
356
204
42
74
134
147
145
164
Changes in Working Capital
-165
-29
-106
-211
-176
-354
38
-192
98
269
Cash after chg. in Working capital
1,627
1,446
859
843
617
344
709
565
638
880
Interest Paid
0
0
0
0
0
0
0
0
0
0
Tax Paid
-344
-292
-197
-203
-246
-133
-149
-94
-74
-81
Other Direct Exp. Paid
0
0
0
0
0
0
0
0
0
0
Extra & Other Items
0
0
0
0
0
0
0
0
0
0
Cash From Investing Activity
-1,559
-714
-684
-498
-1,142
-509
-938
-376
-360
-314
Net Fixed Assets
744
-281
-178
-216
-217
-58
-323
-214
-75
-135
Net Investments
-967
185
-311
-79
-3,688
328
126
38
-171
-67
Others
-1,336
-618
-195
-203
2,763
-779
-741
-200
-113
-112
Cash from Financing Activity
388
-242
-240
-178
1,068
186
426
-9
-186
-275
Net Cash Inflow / Outflow
112
199
-262
-36
296
-112
49
87
18
209
Opening Cash & Equivalents
659
449
710
758
458
557
474
369
359
140
Closing Cash & Equivalent
825
659
449
710
758
463
557
474
369
359

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
55
50
43
40
34
27
24
22
18
16
ROA
7%
9%
5%
8%
8%
9%
8%
12%
9%
12%
ROE
14%
18%
9%
15%
16%
17%
16%
22%
17%
21%
ROCE
14%
16%
9%
13%
14%
15%
16%
22%
17%
20%
Fixed Asset Turnover
0.78
0.85
0.73
0.89
1.05
1.09
1.12
1.11
1.06
0.97
Receivable days
72
78
86
74
80
80
69
72
84
93
Inventory Days
71
58
60
55
54
48
49
56
68
78
Payable days
81
87
88
79
71
58
56
65
70
71
Cash Conversion Cycle
62
49
58
50
63
70
62
63
82
100
Total Debt/Equity
0.40
0.40
0.44
0.48
0.61
0.35
0.30
0.10
0.12
0.17
Interest Cover
20
18
11
33
26
71
317
76
33
19

News Update


  • Biocon’s arm allots equity shares to Tata Capital Growth Fund II
    4th Sep 2020, 10:44 AM

    The company has received approval from board for the allotment of 88 30,456 equity shares of Rs 10 each

    Read More
  • Biocon’s arm, Mylan launch Semglee in US
    1st Sep 2020, 09:15 AM

    Semglee has an identical amino acid sequence to Sanofi’s Lantus and is approved for the same indications

    Read More
  • Tata Capital to invest in Biocon’s arm
    31st Jul 2020, 10:24 AM

    Tata Capital will invest Rs 225 crore for a 0.85% minority stake in the biosimilar business

    Read More
  • Biocon reports 29% fall in Q1 consolidated net profit
    24th Jul 2020, 14:20 PM

    Total income of the company increased by 13.93% at Rs 1689.60 crore for Q1FY21

    Read More
  • Biocon - Quarterly Results
    23rd Jul 2020, 23:05 PM

    Read More
  • Biocon’s arm collaborates with Voluntis to develop, distribute innovative digital therapeutics
    21st Jul 2020, 09:46 AM

    Insulia provides automated insulin dose recommendations enabling people with diabetes to self-manage their condition and healthcare teams to remotely monitor progress

    Read More
  • Biocon gets DCGI’s nod to market Itolizumab Injection
    13th Jul 2020, 08:57 AM

    Itolizumab is the first novel biologic therapy to be approved anywhere in the world for treating patients with moderate to severe COVID-19 complications

    Read More
  • Biocon to invest Rs 1,500 crore on capital expenditure in FY21
    3rd Jul 2020, 09:44 AM

    The company's capital expenditure stood at Rs 974.2 crore during 2019-20

    Read More
  • Biocon’s arm, DKSH collaborate to commercialize seven generic formulations in South East Asia markets
    22nd Jun 2020, 09:33 AM

    This development is in line with Biocon’s strategy for expansion of its generic formulations business through licensing of its drug products in multiple markets

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.